HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: For example, SAHA and FK-228 are broad-spectrum HDAC inhibitors (HDACI) that have been approved by FDA for the treatment of refractory cutaneous T-cell lymphoma (CTCL) [9, 10].